Back to Journals » OncoTargets and Therapy » Volume 11

Successful treatment of metastatic colorectal cancer with apatinib: report of two cases and literature review

Authors Bi MH, Yang JR, Wang YP, Zhang HR, Gao ZY, Zhou HR, Shi MH

Received 6 August 2017

Accepted for publication 28 December 2017

Published 19 February 2018 Volume 2018:11 Pages 883—890

DOI https://doi.org/10.2147/OTT.S148412

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Akshita Wason

Peer reviewer comments 2

Editor who approved publication: Dr Ingrid Espinoza


Video abstract presented by Minghong Bi and Jingru Yang

Views: 201

Minghong Bi,* Jingru Yang,* Yaping Wang, Haoran Zhang, Zhenyuan Gao, Hairong Zhou, Mohan Shi

Department of Medical Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui Province, People’s Republic of China

*These authors contributed equally to this work

Abstract: Apatinib, a novel small molecule tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor-2, was approved for metastatic gastric adenocarcinoma in China in Oct 2014. This is the first report on its use for advanced colorectal cancer as a kind of third-line therapy to date. Here we report two Chinese patients who presented with metastatic colorectal cancer who received apatinib 850 mg daily as a third-line therapy. Both the patients achieved favorable benefits in outcomes after the administration of apatinib. Patient 1 benefited 4 months progression-free survival and 11 months overall survival, while patient 2’s progression-free survival was over 10 months. Both the patients presented hand–foot syndrome, and one of them suffered a slight impairment of liver function, mild elevated blood pressure, and proteinuria. But these adverse events were manageable with symptomatic treatment and dose reduction or a short-time drug withdrawal.

Keywords: vascular endothelial growth factor, large intestine cancer, apatinib, targeted therapy, antiangiogenesis, tyrosine kinase inhibitor

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]